Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 8/20 | 0.56 |
| ▸ | HSD17B1 | P14061 | 6/20 | 0.56 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
| ▸ | MLYCD | O95822 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | DHPS | P49366 | 1/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2454052 | 0.78 | TSHR (0.53) | HSD17B2HSD17B1HTR3EHTR3BCHRNA7 | |
| SCHEMBL772236 | 0.78 | KMO (0.53) | HSD17B2HSD17B1HPGDMEN1GAA | |
| SCHEMBL4449884 | 0.76 | MAPT (0.56) | MLYCDHPGDALDH1A1GAAMAPT | |
| SCHEMBL10367391 | 0.76 | MAPT (0.52) | HSD17B2HSD17B1HTR3EHTR3BCHRNA7 | |
| SCHEMBL938500 | 0.76 | KMO (0.52) | HSD17B2HSD17B1HTR3EHTR3BCHRNA7 | |
| SCHEMBL27605120 | 0.76 | HSD17B1 (0.52) | HSD17B2HSD17B1HTR3EHTR3BCHRNA7 | |
| SCHEMBL28777 | 0.75 | MLYCD (0.54) | TRPM8MLYCDHPGDMEN1ALDH1A1 | |
| SCHEMBL4568046 | 0.74 | DAO (0.53) | MLYCDHPGDALDH1A1KMT2ACLK1 | |
| SCHEMBL111283 | 0.74 | HTR1A (0.47) | HSD17B2MEN1ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL7476159 | 0.73 | MLYCD (0.53) | TRPM8MLYCDHPGDALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-06-12 | — | — | US | disclosed |
| US-12187720-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2025-01-07 | — | — | US | disclosed |
| US-11465987-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | Oncternal Therapeutics, Inc. (US) | 2022-01-27 | — | — | US | disclosed |
| US-11084811-B2 | Compounds for treatment of cancer | Oncternal Therapeutics, Inc. (US) | 2021-08-10 | — | — | US | disclosed |
| EP-2608671-B1 | COMPOUNDS FOR TREATMENT OF CANCER | GTX INC (US) | 2018-12-12 | — | — | EP | disclosed |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTx. Inc. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | GENENTECH, INC. (US) | 2017-01-05 | — | — | US | disclosed |
| US-9447049-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2016-09-20 | — | — | US | disclosed |
| US-9447049-B2 | Compounds for treatment of cancer | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2016-09-20 | — | — | US | disclosed |
| EP-3064204-A1 | COMPOUNDS FOR TREATMENT OF CANCER | GTx, Inc. (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9334242-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| WO-2015142903-A2 | METHOD OF CONTROLLING LACTATE PRODUCTION WITH PIPERDINE-DIONE DERIVATIVES | GENENTECH, INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| US-8822513-B2 | Compounds for treatment of cancer | GTX, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2012-03-22 | — | — | US | disclosed |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | ONCTERNAL THERAPEUTICS, INC | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187720-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | HSD17B2 1371/4885HSD17B1 1191/4885TRPM8 2729/4885 |
| US-20120071524-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | HSD17B2 1371/4885HSD17B1 1191/4885TRPM8 2729/4885 |
| US-20130197049-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | HSD17B2 1371/4885HSD17B1 1191/4885TRPM8 2729/4885 |
| US-20170001990-A1 | PIPERIDINE-DIONE DERIVATIVES | DRD4, ADORA1, ADORA3 | HSD17B2 4047/4885HSD17B1 4029/4885TRPM8 1102/4885 |
| US-11084811-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | HSD17B2 1371/4885HSD17B1 1191/4885TRPM8 2729/4885 |
| US-20220024912-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | HSD17B2 1371/4885HSD17B1 1191/4885TRPM8 2729/4885 |
| US-20170226086-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | HSD17B2 1371/4885HSD17B1 1191/4885TRPM8 2729/4885 |
| US-20110257196-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | HSD17B2 1371/4885HSD17B1 1191/4885TRPM8 2729/4885 |
| US-20250188072-A1 | COMPOUNDS FOR TREATMENT OF CANCER | KLK3, BRDT, ACP3 | HSD17B2 1371/4885HSD17B1 1191/4885TRPM8 2729/4885 |
| US-11465987-B2 | Compounds for treatment of cancer | KLK3, BRDT, ACP3 | HSD17B2 1371/4885HSD17B1 1191/4885TRPM8 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.